Oncology Reviews

, Volume 2, Issue 2, pp 114–116 | Cite as

Treatment of anthracycline extravasation from centrally inserted venous catheters

  • Seppo W. LangerEmail author


The treatment of accidental extravasation of anthracycline-based chemotherapy has markedly improved with the recent introduction of a systemic anti-dote, Savene. However, efficacy data on this treatment is mainly based on extravasation from peripheral catheters. This review presents data on 7 cases of Savene treatment of anthracycline extravasations from central venous catheters.


Anthracycline extravasation Savene (dexrazoxane) Central venous catheter 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mouridsen HT, Langer SW, Buter J et al (2007). Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18:546–550PubMedCrossRefGoogle Scholar
  2. 2.
    Langstein HN, Duman H, Seelig D et al (2002). Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 49:369–374PubMedCrossRefGoogle Scholar
  3. 3.
    Bozkurt AK, Uzel B, Akman C et al (2003). Intrathoracic extravasation of antineoplastic agents: case report and systematic review. Am J Clin Oncol 26:121–123PubMedCrossRefGoogle Scholar
  4. 4.
    Schulmeister L, Camp-Sorrell D (2000). Chemotherapy extravasation from implanted ports. Oncol Nurs Forum 27:531–538PubMedGoogle Scholar
  5. 5.
    Lokich JJ, Moore C (1986). Drug extravasation in cancer chemotherapy. Ann Intern Med 104:124PubMedGoogle Scholar
  6. 6.
    Brothers TE, Von Moll LK, Niederhuber JE et al (1988). Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet 166:295–301PubMedGoogle Scholar
  7. 7.
    Lemmers NW, Gels ME, Sleijfer DT et al (1996). Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol 14:2916–2922PubMedGoogle Scholar
  8. 8.
    Brown DF, Muirhead MJ, Travis PM et al (1997). Mode of chemotherapy does not affect complications with an implantable venous access device. Cancer 80:966–972PubMedCrossRefGoogle Scholar
  9. 9.
    Kock HJ, Pietsch M, Krause U et al (1998). Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22:12–16PubMedCrossRefGoogle Scholar
  10. 10.
    Langer SW, Sehested M, Jensen PB et al (2000). Dexrazoxane in anthracycline extravasation. J Clin Oncol 18:3064PubMedGoogle Scholar
  11. 11.
    El-Saghir N, Otrock Z, Mufarrij A et al (2004). Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol 5:320–321PubMedCrossRefGoogle Scholar
  12. 12.
    Uges JW, Vollaard AM, Wilms EB et al (2006). Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. Int J Clin Oncol 11:467–470PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  1. 1.Dept. of Oncology, section 5073Copenhagen University HospitalRigshospitaletDenmark

Personalised recommendations